Patients may prefer semaglutide injections like Ozempic or Wegovy over daily pills, especially with complex regimens or adherence challenges. Others favor the flexibility of oral forms like Rybelsus, including the option to occasionally skip doses to manage side effects.
FDA Approvals for Semaglutide
Ozempic (semaglutide) gained FDA approval in December 2017 for type 2 diabetes treatment. In 2023, the FDA approved an oral semaglutide formulation, Rybelsus, for the same indication.
The FDA mandates post-market surveillance for safety and efficacy. Check the FDA website for adverse events and recalls.
Patient Preferences: Injections vs Pills
The choice between injectable and oral semaglutide hinges on individual needs. Stanford Health Care highlights that injections suit those struggling with daily pills or managing multiple medications.
- Difficulty swallowing pills
- Gastrointestinal issues affecting absorption
- Preference for less frequent dosing—weekly injections simplify routines
For example, patients with diabetes, hypertension, and hyperlipidemia find weekly shots more convenient than added daily pills.
Travel and Lifestyle Considerations
Frequent travelers or those with irregular schedules may dislike daily pills due to missed doses or carrying challenges. The CDC offers guidance on traveling with medications, including documentation and storage.


